Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07549412RecruitingPhase 3
New chemotherapy drugs for advanced colorectal cancer
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Lone Tree, ColoradoAges 18 years+ - NCT07673627RecruitingPhase 2
Testing empasiprubart for generalized myasthenia gravis
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
Miami, FloridaAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Chandler, ArizonaAges 18 years+ - NCT07673120RecruitingPhase 1
Safety study of ABBV-313 in healthy adults
This study tests a new drug called ABBV-313 in healthy adults to see if it is safe and how the body handles it. You will receive either a single injection or infusion, or multiple doses, to help researchers understand its effects.
Grayslake, IllinoisAges 18–55 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT07663994Recruiting
Blood test validation study for healthy volunteers
This study tests a new method for analyzing DNA in blood to make sure it works correctly. It needs healthy volunteers from the hospital staff to donate a blood sample.
ToulouseAges 18 years+ - NCT07196501RecruitingPhase 3
Study of a new add-on treatment for depression maintenance
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
Oceanside, CaliforniaAges 18 years+ - NCT07726706Enrolling by invitation
Robotic walking device use during school hours
This pilot study tests whether students can use a robotic walking device during the school day. It looks at how well it works and how students and staff feel about using it.
Calgary, AlbertaAges Any age - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Homewood, AlabamaAges 18–100 - NCT07620392RecruitingPhase 2
Long-Term Safety Study of Afimkibart for Rheumatoid Arthritis
This is a follow-up study for people who already completed a previous trial testing afimkibart (an experimental drug) for rheumatoid arthritis. It checks whether the drug continues to work safely and effectively over a longer period.
Tamarac, FloridaAges 18 years+ - NCT07573631Enrolling by invitationPhase 2
Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Milan, ItalyAges 4 years+ - NCT07227311RecruitingPhase 2
Belantamab mafodotin combinations for relapsed multiple myeloma
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Los Alamitos, CaliforniaAges 18 years+ - NCT07556159Recruiting
Asthma Disease Patterns and Outcomes in Everyday Care
This study observes how asthma is managed and controlled in routine clinical practice. Researchers will collect information about your asthma symptoms, treatments, and outcomes over time to better understand real-world asthma management.
Chandler, ArizonaAges 6 years+ - NCT06445517RecruitingPhase 1
ISM8207 for advanced solid tumors and B-cell lymphoma
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Goodyear, ArizonaAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Athens, GeorgiaAges 18 years+ - NCT07037433RecruitingPhase 3
Heart protection study for people with heart disease and overweight
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Daphne, AlabamaAges 45–99 - NCT07399678RecruitingPhase 1
A study of ALV-100 for overweight people with or without type 2 diabetes
This trial tests a new medication called ALV-100 for safety and how well it works in people who are overweight or have type 2 diabetes. It might help if you have a higher body weight and want to try a new treatment option.
Miami, FloridaAges 18–65 - NCT07271693RecruitingPhase 1
Safety study of a new medicine in healthy volunteers
This trial tests a new medicine called RO7806881 in healthy volunteers to see if it is safe, what dose is best, and how the body handles it. It is an early study that helps researchers decide if the drug should be tested in people with a disease.
ChristchurchAges 18–50 - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT07722429Recruiting
Personalized spinal stimulation for arm function after spinal injury
This study tests a personalized electrical stimulation treatment placed near the spine to see if it can improve arm and hand function after a spinal cord injury. If you have a stable injury above the mid-back and have not had new nerve problems in the last 6 months, you may be able to join.
Hualien CityAges 18–70 - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT07721402RecruitingPhase 1
How prifetrastat is absorbed in healthy adults
This study tests how different forms of the study medicine prifetrastat enter the blood. It may help researchers understand the best way to give the medicine in future studies.
Brussels, Bruxelles-capitale, Région deAges 18 years+ - NCT06072482RecruitingPhase 4
Avacopan for ANCA vasculitis (GPA or MPA)
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
Anchorage, AlaskaAges 18–100
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.